Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Large Growth in Short Interest

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a large increase in short interest in November. As of November 30th, there was short interest totalling 120,900 shares, an increase of 19.2% from the November 15th total of 101,400 shares. Based on an average trading volume of 143,400 shares, the short-interest ratio is currently 0.8 days. Currently, 0.5% of the company’s shares are short sold.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, November 13th. Five equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $3.50.

Institutional Investors Weigh In On Bolt Biotherapeutics

A number of hedge funds have recently bought and sold shares of BOLT. Acuitas Investments LLC raised its position in Bolt Biotherapeutics by 21.7% in the 2nd quarter. Acuitas Investments LLC now owns 630,507 shares of the company’s stock valued at $473,000 after purchasing an additional 112,555 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of Bolt Biotherapeutics in the 2nd quarter valued at about $26,000. Finally, FMR LLC increased its holdings in shares of Bolt Biotherapeutics by 33.2% in the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after acquiring an additional 28,773 shares during the last quarter. Institutional investors and hedge funds own 86.70% of the company’s stock.

Bolt Biotherapeutics Price Performance

BOLT opened at $0.53 on Monday. The stock’s 50-day moving average price is $0.62 and its 200 day moving average price is $0.67. Bolt Biotherapeutics has a 12-month low of $0.51 and a 12-month high of $1.56. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.21. The firm has a market cap of $20.20 million, a price-to-earnings ratio of -0.31 and a beta of 0.93.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04). The company had revenue of $1.14 million during the quarter, compared to analyst estimates of $1.02 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. As a group, sell-side analysts expect that Bolt Biotherapeutics will post -1.61 earnings per share for the current year.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.